Pharmacological intervention with a PERK inhibitor in a mouse model of ZIKV infection (IFNɑ/β receptor null mice infected intracerebroventricularly) restored neurogenesis and resulted in an impairment of microcephaly development without affecting viral replication, indicating that PERK activation is involved in ZIKV pathogenesis in the brain but not in viral replication in vivo [83]. The gene discussed is EIF2AK3; the disease is microcephaly.